Loan & DebtMay 28, 2026, 04:09 PM
Viridian Therapeutics Repays $55.1M Loan, Terminates Agreement
AI Summary
Viridian Therapeutics, Inc. announced the voluntary prepayment of approximately $55.1 million, covering all outstanding principal, accrued interest, fees, and expenses under its Loan and Security Agreement. This action, completed on May 27, 2026, resulted in the full satisfaction and discharge of all company obligations and the termination of the Loan Agreement. The original agreement, entered into with Hercules Capital, Inc. and other lenders, provided for a term loan with aggregate maximum borrowings of up to $300 million, of which the company had borrowed $50 million.
Key Highlights
- Viridian Therapeutics completed a voluntary prepayment of approximately $55.1 million.
- The prepayment satisfied and discharged all obligations under the Loan and Security Agreement.
- The Loan Agreement, originally effective April 1, 2022, was terminated.
- The company had borrowed $50 million under the Term Loan facility.
- The Term Loan had an aggregate maximum borrowing capacity of up to $300 million.
- Interest on the loan was a floating rate, greater of 8.95% or 1.45% above Prime Rate, not exceeding 9.45%.
- The original maturity date for the loan was October 1, 2030.
Price Impact
More from VRDN